Blog Hero

Study Reveals Solanezumab Slows Alzheimer’s Disease

Inquire Today

A new research study presented at the Alzheimer’s Association International Conference revealed that the use of the antibody solanezumab reduces the number of amyloid protein clumps (plaques) in the brain using human trials.

What is the Breakthrough Study with Solanezumab?

Eli Lilly (acclaimed pharmaceutical company) has found that solanezumab reduces the plaques that form in Alzheimer’s patients. What adds credence to this study is the fact that it was performed with people, not mice.

Over the course of 3 years, seniors who used the drug for the full time had dramatically fewer plaques than those who had only used it for 2 years.

Trials are going to continue, but should the results prove effective, this drug could be available for Alzheimer’s treatment in 2018.

What is Solanezumab?

The most notable characteristic of Alzheimer’s Disease is the beta-amyloid proteins. These proteins are sticky and when they clump together, they form plaques. The plaques are dangerous because they cause inflammation, devour cells, and block synapses. As Alzheimers progresses and more plaques form, that’s when those suffering lose more memory and even fine motor skills and speech.

However, this is where solanezumab enters into the equation. Solanezumab is an antibody that latches on to amyloid proteins when they’re more soluble and eliminates, thus reducing the chance for plaques to form.

Why haven’t they used Solanezumab in the past?

Actually, they have and many of those trials were discontinued. If that sounds suspect, the reason why is because solanezumab does NOT have a significant impact on those whose dementia has progressed to the severe stages. The drug is effective however against those whose dementia hasn’t progressed beyond a certain stage.

How much of a Breakthrough is this study?

It’s important to temper expectations since this breakthrough is not a cure. However, the results are promising, and the fact that their trials use humans is significant because we’ve seen the effects. More trials are set to continue into 2016, but this could be the start of something revolutionary.

Dr. Doug Brown, the Head of Research at the Alzheimer’s Society, is confident that this antibody treatment is the best way to slow (and potentially stop) the progression of Alzheimer’s Disease.

Written by
Concierge Care Advisors

More Articles By
Concierge Care Advisors

The Top Reviewed Senior Living & Care Company!

Our Testimonials

See what families are saying about
Concierge Care Advisors.

Why Choose Us

No Cost for Families

That’s right, our services are free for families! We are compensated by the community we refer to, giving us the opportunity to help any and all families with this journey.


We take the time to thoroughly vet every community and professional we work with so you receive the quality service you deserve.

Work With
Industry Experts

We’re not just advisors—we’re innovators. We set benchmarks that matter and only work with professionals and communities that meet our standards.

White-Glove Service

You and your loved ones are our focus. From the moment we meet all the way to moving in, we’re by your side every step of the way to ensure your family has the support it deserves.

We Get It Right
The First Time

Start Your Journey

instagram facebook facebook2 pinterest twitter google-plus google linkedin2 yelp youtube phone location calendar share2 link star-full star star-half chevron-right chevron-left chevron-down chevron-up envelope fax